Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs Vanguard Value Index Fund ETF (VTV) Price & Performance

Citius Pharmaceuticals IncTrade
Vanguard Value Index Fund ETFTrade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs Vanguard Value Index Fund ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M), while Vanguard Value Index Fund ETF trades at $226.2. The key difference: Vanguard Value Index Fund ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

CTXRVTV
Market Cap
$20.01M
Sector
Health
52-Week High
$1.82$225.35
52-Week Low
$0.48$179.43
Enterprise Value
$16.23M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.

The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.

Vanguard Value Index Fund ETF

Vanguard Value ETF (VTV) trades at $226.09, up 0.48% with bullish technical signals from moving averages. The ETF focuses on large-cap value stocks and has gained attention for outperforming growth counterparts in 2026, with one Vanguard deep-value fund reportedly up 22% year-to-date according to 247 Wallst on August 10, 2026. Recent institutional activity shows mixed positioning with some firms reducing stakes while others increased holdings.

The outlook remains positive as value strategies gain traction amid tech sector volatility. Key risks include concentration in value stocks and market rotation patterns. Institutional interest persists despite some profit-taking, suggesting continued confidence in the value premium.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR

About Vanguard Value Index Fund ETF

The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.

Read more on VTV